Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00688454 |
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR
Condition |
---|
Hypercholesteremia |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients |
Enrollment: | 3392 |
Study Start Date: | February 2007 |
Study Completion Date: | August 2007 |
Primary Completion Date: | August 2007 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
Pt with hypercholesteremia
Patients treated with CRESTOR because of hypercholesteremia
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins patients
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | AstraZeneca AG, Switzerland ( Dr med Madeleine Billeter ) |
Study ID Numbers: | NIS-CCH-CRE-2007/1 |
Study First Received: | May 29, 2008 |
Last Updated: | June 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00688454 |
Health Authority: | Switzerland: Ethikkommission |
Hyperlipidemia Rosuvastatin Efficacy tolerability CRESTOR therapy |
Rosuvastatin Metabolic Diseases Hyperlipidemias Metabolic disorder |
Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |